Related Experiment Video
Updated: Feb 26, 2026
13:24
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
12.3K
Triple-Negative Breast Cancer: Next-Generation Sequencing for Target Identification
Jonathan D Marotti1, Francine B de Abreu1, Wendy A Wells1
1Department of Pathology and Laboratory Medicine, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover; and the Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
The American Journal of Pathology
|July 24, 2017
Summary
Triple-negative breast cancer (TNBC) is a complex disease. Genomic studies reveal subtypes that improve understanding, guiding precision medicine for better outcomes.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Breast cancer is a heterogeneous disease with diverse subtypes.
- Triple-negative breast cancer (TNBC) lacks estrogen/progesterone receptors and HER2 amplification.
- Molecular profiling is crucial for understanding TNBC's biological variability.
Purpose of the Study:
- To review genomic findings in triple-negative breast cancer.
- To discuss the role of precision medicine in TNBC treatment.
Main Methods:
- Analysis of data from microarrays and next-generation sequencing.
- Review of current literature on TNBC genomics and precision medicine.
Main Results:
- Genomic and somatic mutation profiling identifies TNBC subsets.
- These subsets more accurately reflect biological behavior.
- Molecular insights offer potential for novel therapeutic targets.
Conclusions:
- Genomic characterization is key to understanding TNBC heterogeneity.
- Precision medicine approaches informed by genomic data hold promise for improved TNBC prognosis and outcomes.
